Premium
P‐Glycoprotein‐Dependent Trafficking of Nanoparticle‐Drug Conjugates
Author(s) -
Dreaden Erik C.,
Raji Idris O.,
Austin Lauren A.,
Fathi Shaghayegh,
Mwakwari Sandra C.,
Humphries William H.,
Kang Bin,
Oyelere Adegboyega K.,
ElSayed Mostafa A.
Publication year - 2014
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201303190
Subject(s) - p glycoprotein , multiple drug resistance , drug , conjugated system , conjugate , drug delivery , nanoparticle , substrate (aquarium) , chemistry , nanotechnology , materials science , pharmacology , biochemistry , medicine , biology , antibiotics , polymer , mathematical analysis , mathematics , ecology , organic chemistry
P‐glycoprotein (P‐gp) is considered to be the most prevalent and single most important cause of multidrug‐resistance (MDR) in humans . Although the protein is well known to modulate the cellular trafficking of small molecule fluorophores, antimicrobials, and up to 50% of all cytotoxic chemotherapeutics, little is known about its interactions with nanoscale drug conjugates. Here, we use P‐gp substrate‐conjugated gold nanorods as model drug carriers to investigate P‐gp‐dependent cellular trafficking of nanoparticles.